Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone OLE in partial-onset seizures
NCT00512317Phase 2Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Jun 2007
- Primary completion
- Dec 2009
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ganaxolone in focal onset seizure, sponsored by Marinus Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Weekly Seizure Frequency at Week 117. Started Jun 2007; status: completed.
02
Drugs
ganaxolone
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT00512317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00512317.